Y Intercept Hong Kong Ltd Sells 38,937 Shares of Guardant Health, Inc. (NASDAQ:GH)

Y Intercept Hong Kong Ltd trimmed its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 76.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,936 shares of the company's stock after selling 38,937 shares during the period. Y Intercept Hong Kong Ltd's holdings in Guardant Health were worth $274,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock worth $102,000 after acquiring an additional 796 shares in the last quarter. JNBA Financial Advisors bought a new position in Guardant Health in the third quarter valued at $26,000. Wexford Capital LP increased its stake in Guardant Health by 13.0% in the 3rd quarter. Wexford Capital LP now owns 10,081 shares of the company's stock valued at $231,000 after buying an additional 1,158 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Guardant Health during the 3rd quarter worth about $34,000. Finally, Quarry LP bought a new position in shares of Guardant Health in the 2nd quarter valued at about $44,000. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on GH shares. The Goldman Sachs Group increased their price target on shares of Guardant Health from $32.00 to $36.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Leerink Partners dropped their price objective on Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Sanford C. Bernstein dropped their price target on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 30th. Finally, UBS Group lifted their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, August 21st. Fifteen investment analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health has a consensus rating of "Buy" and an average target price of $40.60.

Guardant Health Price Performance

Shares of NASDAQ GH traded down $1.23 during midday trading on Thursday, reaching $31.13. The company's stock had a trading volume of 1,817,431 shares, compared to its average volume of 2,033,935. The company has a market cap of $3.85 billion, a P/E ratio of -7.34 and a beta of 1.26. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $38.53. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. The business's 50 day moving average price is $28.71 and its two-hundred day moving average price is $28.30.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the previous year, the company posted ($0.73) earnings per share. The business's revenue was up 33.9% compared to the same quarter last year. On average, analysts forecast that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares of the company's stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,432 shares of company stock valued at $175,423 in the last ninety days. 5.50% of the stock is currently owned by company insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.